MCO Molecular and Clinical Oncology 2049-9450 2049-9469 D.A. Spandidos 10.3892/mco.2016.963 MCO-0-0-963 Articles Effects of treatment with an Hsp90 inhibitor in tumors based on 15 phase II clinical trials WangHe 1 * LuMingjie 2 * YaoMengqian 2 ZhuWei 2 Department of Oncology, The Third Affiliated Hospital of Nanjing Medical University, Nanjing 211100, P.R. China Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, P.R. China Correspondence to: Dr Wei Zhu, Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, P.R. China, E-mail: zhuwei@njmu.edu.cn

Contributed equally

 09 2016 19 07 2016 5 3 326 334 15022016 01072016 Copyright © 2016, Spandidos Publications 2016

Heat shock protein (Hsp)90 serves as a chaperone protein that promotes the proper folding of proteins involved in a variety of signal transduction processes involved in cell growth. Hsp90 inhibitors, which inhibit the activity of critical client proteins, have emerged as the accessory therapeutic agents for multiple human cancer types. To better understand the effects of Hsp90 inhibitors in cancer treatment, the present study reviewed 15 published phase II clinical trials to investigate whether Hsp90 inhibitors will benefit patients with cancer. Information of complete response, partial response, stable disease, objective response and objective response rate was collected to evaluate clinical outcomes. Overall, Hsp90 inhibitors are effective against a variety of oncogene-addicted cancers, including those that have developed resistance to specific receptors.

 Hsp90 inhibitor clinical trial genotype tumor Introduction

Tumors are one of the most common lethal diseases worldwide, with 14 million new cases diagnosed annually. They are also the leading cause of mortality worldwide, causing 8.2 million mortalities annually, as reported in the World Health Organization World Cancer Report 2014. Although cytotoxic chemotherapy has revolutionized the prognosis for patients with most tumor types, survival remains dismal as a whole and exploring the novel therapeutic approaches is required. Considering that oncoproteins serve a pivotal role in tumorigenesis, molecular target therapies in different types of tumor have been more and more crucial and promising.

The molecular chaperone, heat shock protein (Hsp)90, serves an important role in the formation, stability and function of the proteins involved in cell growth and survival signaling pathways (1). The ability of Hsp90 to chaperone protein kinases or transcription factors is dependent on the binding and hydrolysis of ATP at its binding domain (2). Accordingly, multiple mitogenic pathways may be inhibited by synthetic inhibitors of the Hsp90 ATPase activity, including 17-allylamino-17-demthoxygeldanamycin (17-AAG), ganetespib, retaspimycin HCl (IPI-504) and BIIB021 (3–7). Evidence of the activity of Hsp90 inhibitors was shown in vitro, and animal models of different types of tumor and numerous clinical trials were performed to search for novel treatments against tumors (8–12). The present study summarized 15 phase II clinical trials using Hsp90 inhibitors and found that the lack of efficacy of Hsp90 inhibitors in these initial phase II studies may be due to the treatment-associated toxicity limitation, accounting for insufficient dose of drug or infrequent schedule of administration, which in turn leads to inadequate inhibition of target proteins. Additionally, the clinical activity of Hsp90 inhibitors suggested a potential cancer therapy against a variety of oncogene-addicted cancer types, including those that have developed resistance to specific receptors.

 Methods and materials <sec> <title>Identification of eligible studies

PubMed (http://www.ncbi.nlm.nih.gov/pubmed) was searched using the search terms (last search updated 10th December 2015) ‘Hsp90 inhibitor’ and ‘cancer’ with no limitations. In addition, another search strategy was also performed using the terms ‘Hsp90 inhibitor’ (limited to humans), ‘clinical trial’ and ‘cancer’. Information found on the ClinicalTrials.gov website (www.clinicaltrials.gov), a registry and results database of publicly and privately supported clinical studies using human participants performed worldwide, was also reviewed. All relevant publications were reviewed and duplications of articles from the two search strategies were eliminated. The articles in reference lists were also hand-searched for potentially relevant publications. The search was performed by two investigators. Any disagreements were resolved by consensus with the involvement of a third author.

 Inclusion criteria

All human-associated studies, regardless of tumor types, were included once they met the following criteria: Malignant tumor, monotherapy with Hsp90 inhibitor or Hsp90 inhibitor combined with other antitumor drugs, histological confirmation, relatively stable administration dosage of Hsp90 inhibitor and sufficient data of clinical outcomes.

 Data extraction

Two investigators extracted data independently and reached a consensus on all items. For each study, the following information was collected: First author, year of publication, country of the first author, the number of total and evaluable patients, median age, gender, cancer type, stage, prior treatment, name of Hsp90 inhibitor or other combined drugs, dose regimen, median cycle of treatment, clinical outcomes, including the number of patients who achieved stable disease (SD), partial response (PR), complete response (CR), objective response (OR) or progressive disease (PD). Other evaluation data, including the median overall survival (OS), progression-free survival (PFS), time to progression (TTP) and response of duration (DR) were also collected. For studies including different tumor types, data were extracted separately by tumor types if there was enough information in the text. Additionally, the studies mentioning genomic alteration were extracted separately to investigate if Hsp90 inhibitors have the ability to overcome resistance to receptor-specific targeted treatments.

 Results <sec> <title>Literature search

A total of 1,261 published articles were identified from PubMed and 1,110 duplicated and unrelated articles were excluded. Within the remaining 50 publications related to clinical trials, articles were excluded if administration dosage of Hsp90 inhibitor was not stable; all Phase I studies were excluded for this reason. Therefore, a total of 15 articles were eligible for assessment in the present study. Of these 15 articles, 9 mentioned that genomic alteration were extracted separately, as discussed later.

Due to the heterogeneity of patients, Hsp90 inhibitor types, regimens, clinical settings and a large variety of outcome measurement used in these trials and pooling of data for meta-analysis was inappropriate. The results were, therefore, summarized qualitatively.

 Study characteristics

Details from 15 eligible trials published between 2006 and 2014 were analyzed in Table I. All first authors were based in the USA. The number of patients in these trials ranged between 11 and 99, with the median age between 51 and 68 years. A total of 10 types of cancer were described in these 15 trials, including breast cancer (13–16), ovarian carcinoma (17), peritoneal carcinoma (17), multiple myeloma (18), renal cell cancer (19), prostate cancer (20,21), melanoma (22,23), colorectal cancer (24), lung cancer (25,26) and gastrointestinal stromal tumor (GIST) (27). The majority of patients had received prior therapies and had metastatic or recurrent diseases at baseline.

 Treatment administration

Details of eligible trials with an Hsp90 inhibitor were noted in Table II. The majority of Hsp90 inhibitors were tested in trials of monotherapy: 17-AAG (13,19,20,23), ganetespib (15,24,25), IPI-504 (21,26) and BIIB021 (27). There were also trials of combination of Hsp90 inhibitors, 17-AAG (14,17,18)/IPI-504 (16), with other anticancer drugs, including cytotoxic and molecularly targeted agents.

The majority of Hsp90 inhibitors were administered by intravenous infusion. For 17-AAG, the dosage was 50/175/220/340 mg/m2 on days 1, 4, 8 and 11 of a 21-day cycle; or 300/450 mg/m2 on days 1, 8 and 15 of a 28-day cycle; 154 mg/m2 on days 1, 8 (1,9) of a 21-day cycle; 450 mg/m2 weekly. For ganetespib, the dosage was 200 mg/m2 on days 1, 8 and 15 of a 28-day cycle. For IPI-504, the dosage was 400 mg/m2 on days 1, 4 8 and 11 of a 21-day cycle or 300 mg/m2 weekly. Treatment with BIIB021 was administered as a 600 mg dose twice a week or 400 mg three times a week. The median cycle of each treatment was summarized in Table II.

In trials combining an Hsp90 inhibitor with other drugs, three added the molecularly targeted agent trastuzumab/bortezomib to 17-AGG or IPI-504, and one added the cytotoxic drug gemcitabine to 17-AGG (14,16–18). The median cycle of each treatment was summarized in Table II.

 Clinical outcomes

Response criteria were used, as defined by the Response Evaluation Criteria in Solid Tumors (12–15, 17,20,22–26), the European Group for Bone and Marrow Transplantation criteria (18), the Prostate-Specific Antigen Working Group (19), the NCI Prostate-Specific Antigen Working Group (21) and the EORTC guidelines (27). Overall, Hsp90 inhibitors are effective against a variety of oncogene-addicted cancer types, including those that have developed resistance to specific receptors.

Of the 15 trials that used Hsp90 inhibitors, OR was observed in 7 studies, with ORR ranging between 0.04 and 0.22, demonstrating that in tumors driven by client proteins are hypersensitive to Hsp90 inhibition at the currently deliverable doses and schedules (14,15,17,18,25–27). Modi et al (14) demonstrated that 17-AAG is effective in advanced trastuzumab-refractory human epidermal growth factor receptor (HER)2-positive breast cancer. In that previous study, the OR was 22%, the clinical benefit rate (CR + PR + SD) was 59%, the median PFS was 6 months and the median OS was 17 months. Consistent results were observed in metastatic breast cancer (MBC) that used ganetespib as a single agent, the clinical benefit rate (CR + PR + SD >6 months) was 9%, median PFS was 7 weeks and median OS was 46 weeks (15). Socinski et al (25) found that ganetespib showed encouraging single-agent activity in heavily pretreated chemotherapy patients with advanced non-small cell lung cancer (NSCLC) that harbored anaplastic lymphoma kinase (ALK) rearrangement. Sequist et al (26) observed the identical phenomenon in the trial using IPI-504. Among the three patients with NSCLC harboring the ALK rearrangement, which progressed following epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy, two had PR and the third had prolonged SD. OR was also observed in trials that used 17-AAG combined with gemcitabine (17) or bortezomib (18). This was also observed in trials combining IPI-504 with these drugs (27). The authors hypothesized that an Hsp90 inhibitor performed the action efficiently by degrading the client proteins, including Chk1, proteasome, c-Kit and platelet-derived growth factor receptor α. The results mentioned above were relative to oncogenes, and therefore, the present study extracted trials using the Hsp90 inhibitor in tumors harboring genotype alteration to explore whether the Hsp90 inhibitor has the ability to overcome resistance to receptor-specific targeted treatments. The results are shown in Table III.

Additionally, trials that failed to achieve OR are also summarized in Table II. The lack of efficacy of Hsp90 inhibitors in these initial phase II studies may be due to treatment-associated toxicity limitations, accounting for insufficient dose of drug or infrequent schedule of administration, which leads to the lack of adequate inhibition of target proteins.

 Discussion

Hsp90 is a chaperone for a wide variety of signaling proteins, many of which serve an important role in tumorigenesis, including HER2, EGFR, Akt, c-RAF, BRAF and re-arranged ALK (28–33). Loss of Hsp90 function leads to ubiquitination and degradation of these proteins, causing cell growth inhibition, apoptosis of tumor cells and antitumor activity in preclinical models (8–12). These preclinical observations have prompted the clinical assessment of Hsp90 inhibitors in various tumor types.

The present review summarized 15 phase II clinical trials of different types of tumor and found that the Hsp90 inhibitor may be a potential agent against tumors via the inhibition of intended client proteins. Modi et al (14) and Socinski et al (15) have proved the antitumor activity of 17-AAG and ganetespib, respectively, for patients with HER2-positive MBC which progressed following trastuzumab administration. Notably, p95HER2 is an Hsp90 target that is degraded by Hsp90 inhibitors (28). Furthermore, trastuzumab-resistant models with overexpression of p95HER2 are sensitive to Hsp90 inhibitors. Sustained loss of HER2 and p95HER2 expression, and inhibition of AKT activation with regulatory administration of Hsp90 inhibitors resulted in apoptosis of cancer cells and inhibition of tumor growth. Data from previous studies of NSCLC show that lower concentrations of Hsp90 inhibitors may be required to inhibit the expression of echinoderm microtubule associated protein like 4-ALK compared with mutant EGFR, all of which had previously received and acquired resistance to lines of chemotherapy or EGFR TKIs, respectively (25,26). Additionally, induction of small cell histological changes or epithelial-mesenchymal transition may have been present in certain cases and may have contributed to the lack of durable clinical activity for patients with EGFR mutations with Hsp90 inhibitors (29).

Tillotson et al (30) revealed that Hsp70 may be a biomarker for predicting the antitumor activity of Hsp90 inhibitors (30). Furthermore, the authors demonstrated that response to Hsp90 inhibitors is correlated to the extent of downregulation of client proteins, which relies on occupancy of Hsp90 (30–33). Inhibition of Hsp90 may induce bortezomib-triggered apoptosis, even in drug-resistant multiple myeloma cells, due to upregulation of plasma Hsp70 and downregulation of proteasomal activity (18). Although partial downregulation of Chk1 was observed after 17-AAG administration, the 17-AAG/gemcitabine combination showed limited anticancer activity in patients with advanced epithelial ovarian and primary peritoneal carcinoma, probably attributed to insufficient downregulation of client proteins, including HER2, insulin-like growth factor 1 receptor, insulin receptor, Akt and c-Raf, at currently used doses (17). Accumulating evidence has suggested that the interaction of client proteins with the Hsp90 chaperone is a multifaceted process, with certain kinases forming stable heterocomplexes with the chaperone machinery and others forming more dynamic complexes that are more readily disassembled, and in which the client is more modestly ubiquitinated (34). These differences may contribute to the hierarchy of sensitivity of clients to degradation.

The lack of efficacy of Hsp90 inhibitors in these initial phase II studies may be due to the treatment-associated toxicity limitation accounting for insufficient dose of drug or infrequent schedule of administration, which leads to the lack of adequate inhibition of target proteins. Although overexpression of Hsp72 and low expression of Hsp90 were detected, the client proteins, including HER2 and cyclin-dependent kinase (CDK)4 depletion were not consistently detected in patients with metastatic melanoma (23). The lack of objective tumor responses is consistent with what has been reported in hormone-refractory prostate cancer (20) and in renal cell carcinoma (19) using lower doses of 17-AAG. No significant changes in interleukin (IL)-6, IL-8 and maspin in metastatic, hormone-refractory prostate cancer with 17-AAG may lead to failure of prostate-specific antigen response (20). Preclinical studies have demonstrated that both suppression of client proteins within 24–72 h and sufficient administration of Hsp90 inhibitors are required to induce antitumor effects (35). At the time of the posttreatment biopsy (median, 44 h after dose 1), an increase in Hsp70 levels and a decrease in cyclin D1 levels were detected (22). These findings, together with the observation of changes in RAF-1 and CDK4 at 24 h in another study (32), suggested that transient decreases in raf kinases, phosphorylated-extracellular signal-regulated kinase-1 and CDK4 may have occurred. However, these changes in the components of the mitogen-activated protein kinase pathway were not sufficient to cause tumor shrinkage. Clinically, frequent dosing schedules have been restricted by the toxicity observed in patients. The death of two patients with castration-resistant prostate cancer, treated with IPI-504 at a dose of 400 mg/m2 on days 1, 4, 8 and 11 of a 21-day cycle, was a result of drug-related events of hepatic failure and ketoacidosis, respectively (21).

In conclusion, only tumor types driven by client proteins that are hypersensitive to Hsp90 inhibition will be susceptible to the effects of Hsp90 inhibitors at the currently doses and schedules. The present review summarized 15 phase II clinical trials using Hsp90 inhibitors and found that Hsp90 inhibitors may be a potential cancer therapy against a variety of oncogene-addicted cancer types, including those developing resistance to specific receptors.

 Acknowledgements

The present study was funded by the continuous financial support from the National Natural Science Foundation of China Youth Found (no. 81501980).

 References TaipaleMJaroszDFLindquistSHSP90 at the hub of protein homeostasis: Emerging mechanistic insightsNat Rev Mol Cell Biol11515528201010.1038/nrm291820531426 MeissnerAPetersennSHeidemannHTOsterkampUSimonRSchulteHMPharmacokinetics of oral isosorbide-5-mononitrate in patients with ischemic heart failureKlin Wochenschr69213219199110.1007/BF016469432033915 RamanathanRKTrumpDLEisemanJLBelaniCPAgarwalaSSZuhowskiEGLanJPotterDMIvySPRamalingamSPhase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancersClin Cancer Res1133853391200510.1158/1078-0432.CCR-04-232215867239 GremJLMorrisonGGuoXDAgnewETakimotoCHThomasRSzaboEGrochowLGrollmanFHamiltonJMPhase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumorsJ Clin Oncol2318851893200510.1200/JCO.2005.12.08515774780 GoldmanJWRajuRNGordonGAEl-HariryITeofiliviciFVukovicVMBradleyRKarolMDChenYGuoWA first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignanciesBMC Cancer13152201310.1186/1471-2407-13-15223530663 SaifMWTakimotoCMitaMBanerjiULamannaNCastroJO'BrienSStogardCVon HoffDA phase 1, dose-escalation, pharmacokinetic and pharmacodynamic study of BIIB021 administered orally in patients with advanced solid tumorsClin Cancer Res20445455201410.1158/1078-0432.CCR-13-125724097863 WagnerAJChughRRosenLSMorganJAGeorgeSGordonMDunbarJNormantEGrayzelDDemetriGDA phase 1 study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomasClin Cancer Res1960206029201310.1158/1078-0432.CCR-13-095324045182 UozakiHIshidaTKakiuchiCHoriuchiHGotohTIijimaTImamuraTMachinamiRExpression of heat shock proteins in osteosarcoma and its relationship to prognosisPathol Res Pract196665673200010.1016/S0344-0338(00)80118-111087053 ChiosisGNeckersLTumor selectivity of Hsp90 inhibitors: The explanation remains elusiveACS Chem Biol1279284200610.1021/cb600224w17163756 MoulickKAhnJHZongHRodinaACerchiettiLDa Gomes GamaEMCaldas-LopesEBeebeKPernaFHatziKAffinity-based proteomics reveal cancer-specific networks coordinated by Hsp90Nat Chem Biol7818826201110.1038/nchembio.67021946277 Garcia-CarboneroRCarneroAPaz-AresLInhibition of HSP90 molecular chaperones: Moving into the clinicLancet Oncol14e358e369201310.1016/S1470-2045(13)70169-423896275 TaldoneTPatelHJBolaenderAPatelMRChiosisGProtein chaperones: A composition of matter review (2008-2013)Expert Opin Ther Pat24501518201410.1517/13543776.2014.88768124742089 GartnerEMSilvermanPSimonMFlahertyLAbramsJIvyPLorussoPMA phase II study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast cancerBreast Cancer Res Treat131933937201210.1007/s10549-011-1866-722083229 ModiSStopeckALindenHSolitDChandarlapatySRosenND'AndreaGDicklerMMoynahanMESugarmanSHSP90 inhibition is effective in breast cancer: A phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumabClin Cancer Res1751325139201110.1158/1078-0432.CCR-11-007221558407 JhaveriKChandarlapatySLakeDGilewskiTRobsonMGoldfarbSDrullinskyPSugarmanSWasserheit-LeiblichCFasanoJA phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancerClin Breast Cancer14154160201410.1016/j.clbc.2013.12.01224512858 ModiSSauraCHendersonCLinNUMahtaniRGoddardJRodenasEHudisCO'ShaughnessyJBaselgaJA multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancerBreast Cancer Res Treat139107113201310.1007/s10549-013-2510-523580070 HendricksonAEObergALGlaserGCamorianoJKPeethambaramPPColon-OteroGErlichmanCIvySPKaufmannSHKarnitzLMHaluskaPA phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinomaGynecol Oncol124210215201210.1016/j.ygyno.2011.10.00222047770 RichardsonPGBadrosAZJagannathSTarantoloSWolfJLAlbitarMBermanDMessinaMAndersonKCTanespimycin with bortezomib: Activity in relapsed/refractory patients with multiple myelomaBr J Haematol150428437201020618338 RonnenEAKondaguntaGVIshillNSweeneySMDelucaJKSchwartzLBacikJMotzerRJA phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinomaInvest New Drugs24543546200610.1007/s10637-006-9208-z16832603 HeathEIGaskinsMPitotHCPiliRTanWMarschkeRLiuGHillmanDSarkarFShengSA phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancerClin Prostate Cancer4138141200510.3816/CGC.2005.n.02416197617 OhWKGalskyMDStadlerWMSrinivasSChuFBubleyGGoddardJDunbarJRossRWMulticenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancerUrology78626630201110.1016/j.urology.2011.04.04121762967 SolitDBOsmanIPolskyDPanageasKSDaudAGoydosJSTeitcherJWolchokJDGerminoFJKrownSEPhase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanomaClin Cancer Res1483028307200810.1158/1078-0432.CCR-08-100219088048 PaceySGoreMChaoDBanerjiULarkinJSarkerSOwenKAsadYRaynaudFWaltonMA Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanomaInvest New Drugs30341349201210.1007/s10637-010-9493-420683637 CercekAShiaJGollubMChouJFCapanuMRaaschPReidy-LagunesDProiaDAVakianiESolitDBSaltzLBGanetespib, a novel Hsp90 inhibitor in patients with KRAS mutated and wild type, refractory metastatic colorectal cancerClin Colorectal Cancer13207212201410.1016/j.clcc.2014.09.00125444464 SocinskiMAGoldmanJEl-HariryIKoczywasMVukovicVHornLPascholdESalgiaRWestHSequistLVA multicenter phase II study of ganetespibmonotherapy in patients with genotypically defined advanced non-small cell lung cancerClin Cancer Res1930683077201310.1158/1078-0432.CCR-12-338123553849 SequistLVGettingerSSenzerNNMartinsRGJännePALilenbaumRGrayJEIafrateAJKatayamaRHafeezNActivity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancerJ Clin Oncol2849534960201010.1200/JCO.2010.30.833820940188 DicksonMAOkunoSHKeohanMLMakiRGD'AdamoDRAkhurstTJAntonescuCRSchwartzGKPhase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumorsAnn Oncol24252257201310.1093/annonc/mds27522898035 ChandarlapatySScaltritiMAngeliniPYeQGuzmanMHudisCANortonLSolitDBArribasJBaselgaJRosenNInhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growthOncogene29325334201010.1038/onc.2009.33719855434 SequistLVWaltmanBADias-SantagataDDigumarthySTurkeABFidiasPBergethonKShawATGettingerSCosperAKGenotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitorsSci Trans Med375ra26201110.1126/scitranslmed.3002003 TillotsonBSlocumKCocoJWhitebreadNThomasBWestKAMacDougallJGeJAliJAPalombellaVJHsp90 (heat shock protein 90) inhibitor occupancy is a direct determinant of client protein degradation and tumor growth arrest in vivoJ Biol Chem2853983539843201010.1074/jbc.M110.14158020940293 GoetzMPToftDReidJAmesMStensgardBSafgrenSAdjeiAASloanJAthertonPVasileVPhase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancerJ Clin Oncol2310781087200510.1200/JCO.2005.09.11915718306 BanerjiUO'DonnellAScurrMPaceySStapletonSAsadYSimmonsLMaloneyARaynaudFCampbellMPhase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignanciesJ Clin Oncol2341524161200510.1200/JCO.2005.00.61215961763 NowakowskiGSMcCollumAKAmesMMMandrekarSJReidJMAdjeiAAToftDOSafgrenSLErlichmanCA phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancerClin Cancer Res1260876093200610.1158/1078-0432.CCR-06-101517062684 PrattWBMorishimaYPengHMOsawaYProposal for a role of the Hsp90/Hsp70-based chaperone machinery in making triage decisions when proteins undergo oxidative and toxic damageExp Biol Med (Maywood)235278289201010.1258/ebm.2009.00925020404045 SolitDBBassoADOlshenABScherHIRosenNInhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to TaxolCancer Res6321392144200312727831

Characteristics of trials using an Hsp90 inhibitor.

Patient characteristics
Trial Authors, year Total number Median age (years) Gender (male/female) Cancer type Status Prior treatment (no. patients) Refs.
1 Gartner et al, 2012 11 (7a) 54 0/11 Breast Locally advanced or metastatic Chemotherapy (all) Hormonal therapy (all) (13)
2 Modi et al, 2011 31 (27a) 53 1/30 Breast Metastatic Chemotherapy (n=25) Trastuzumab therapy (all) (14)
3 Jhaveri et al, 2014 22 (6/13/3)f 51 0/22 Breast Metastatic Chemotherapy (all) Trastuzumab therapy (n=12) (15)
4 Modi et al, 2013 26 53 1/25 Breast Locally advanced or metastatic Chemotherapy (all) trastuzumab therapy (all) (16)
5 Hendrickson et al, 2012 29 (11/14a)b 68/65.5 0/25 Ovarian Peritoneal Relapsed or persistent Chemotherapy (n=25) (17)
6 Richardson et al, 2010 22 (8/8/6)c 62.5 14/8 Multiple myeloma Relapsed or refractory Prior-SCT (n=18) Chemotherapy (all) (18)
7 Ronnen et al, 2006 20 (12/8)d 68 14/6 Renal Metastatic Nephrectomy (n=8/7) Radiation (n=4/2) Immunotherapy (n=11/2) Chemotherapy or hormonal (n=2/0) (19)
8 Heath et al, 2005 17 (15a) 68 15/0 Prostate Metastatic Prostatectomy (n=5) Chemotherapy (n=13) Radiation therapy (n=12) Androgen ablation (n=14) (20)
9 Oh et al, 2011 19 (4/15)h 68.5/60 0/19 Prostate Castration-resistant Chemotherapy (n=15) hormonal therapy (majority of patients) (21)
10 Solit et al, 2008 15 (6/9)e 66/55 12/3 Melanoma Stage III/IV Chemotherapy (n=5/9) (22)
11 Pacey et al, 2012 14 (11a) 60 8/6 Melanoma Metastatic Surgery (n=14) Chemotherapy (n=13) Radiotherapy (n=2) Immunotherapy (n=5) Molecularly targeted agent (n=5) Isolated limb perfusion (n=2) (23)
12 Cercek et al, 2014 17 58 11/6 Colorectal Metastatic Chemotherapy (all) Anti-EGFR (patients with KRAS wild-type: 6) (24)
13 Socinski et al, 2013 99 (15/17/66)g 61 47/52 Lung (NSCLC) Stage IIIB/IV Systemic therapy (all) (25)
14 Sequist et al, 2010 76 64 28/48 Lung (NSCLC) Stage IIIB/IV Systemic therapy (all) EGFR TKIs (all) (26)
15 Dickson et al, 2013 23 59 14/9 GIST Refractory Imatinib (all) sunitinib (all) sorafenib (n=14) nilotinib (n=2) (27)

The number of patients eligible for the assessment of clinical outcomes.

Patients enrolled in two groups, eotjer exposure to gemcitabine or not, which also apply to the following data.

Patients were divided into three groups of dosage with 340, 175 or 50 mg/m2.

Patients enrolled in clear-cell RCC cohort or papillary RCC, which also apply to the following data.

Patients with wild-type or mutant BRAF.

Subtype of ER(+)/HER-2(−), HER-2(+) and triple negative breast cancer.

Subtype of mutant EGFR, mutant KRAS and wild-type EGFR or KRAS.

Patients of chemotherapy-naïve or docetaxel-treated. SCT, stem cell transplant; NSCLC, non-small cell lung cancer; RCC, renal cell carcinoma; EGFR, epidermal growth factor receptor: ER, estrogen receptor; HER, human epidermal growth factor receptor; GIST, gastrointestinal stromal tumors; TKIs, tyrosine kinase inhibitors; IVD, intravenous dose; NA, not available.

Treatment administration and clinical outcomes of the studies that used Hsp90 inhibitor.

Treatment administration Clinical outcomes
Trial Cancer type Drug Dose regime Median cycles PR CR OR ORR SD PD Others (median)
1 Breast 17-AAG 220 mg/m2 IVD on days 1, 4, 8 and 11 of a 21-day cycle 2 0 0 0 0 3 4 PFS: 1 month OS: 10 months
2 Breast 17-AAG + Trastuzumab 450 mg/m2 iv. + 2 mg/kg iv. weekly (intial dose of 4 mg/kg was >21 days prior to the present study NA 6 0 6 0.22 10 11 PFS: 6 months OS: 17 months DR: 147 days
3 Breast Ganetespib 200 mg/m2 IVD days 1, 8 and 15 of a 28-day cycle NA 0/2/0e 0/0/0 0/2/0 0.09 0/6/1 NA PFS: 7 weeks OS: 46 week
4 Breast IPI-504 Trastuzumab 300 mg/m2 iv. weekly plus trastuzumab 6 mg/kg iv. every 3 weeks (intial dose of 8 mg/kg for patients whose last trastuzumab therapy was >4 weeks prior to study entry) 3g 0 0 0 0 16 NA NA
5 Ovarian Peritoneal 17-AAG + Gemcitabine 154 mg/m2 iv. on days 1 and 8, days 1 and 9 of subsequent cycles + 750 mg/m2 iv. gemcitabine on day 7 (days 1 and 8 of subsequent cycles) of a 21-day cycle 4/3.5a 0/1 0/0 0/1 0.04 4/2 7/11 OS: 11.5/18.3 months TTP: 2.7/1.6 months
6 Multiple myeloma 17-AAG + Bortezomib 340/175/50 mg/m2 iv. plus bortezomib + 1.3 mg/m2 on days 1, 4, 8 and 11 of a 21-day cycle NA 2 0 3b 0.14 10 NA NA
7 Renal 17-AAG 220 mg/m2 IVD days 1, 4, 8 and 11 of a 21-day cycle NA 0 0 0 0 9/5c NA TTP: 3.3/1.6 months
8 Prostate 17-AAG 300 mg/m2 IVD days 1, 8 and 15 of a 28-day cycle 2 0 0 0 0 1 13 TTP: 1.8 months 6-month OS: 71%
9 Prostate IPI-504 400 mg/m2 IVD days 1, 4, 8 and 11 of a 21-day cycleh 2 0 0 0 0 1 NA NA
10 Melanoma 17-AAG 450 mg/m2 IVD weekly (6/8-week cycle) 5 dose 0 0 0 0 1 14 NA
11 Melanoma 17-AAG 450 mg/m2 IVD weekly 10 0 0 0 0 3 8 OS: 232 days
12 Colorectal Ganetespib 200 mg/m2 IVD days 1, 8 and 15 of a 28-day cycle NA 0 0 0 0 2d NA PFS: 1.6 months OS: 5.1 months 6-month OS: 71%
13 Lung (NSCLC) Ganetespib 200 mg/m2 IVD days 1, 8 and 15 of a 28-day cycle NA 0/0/4f 0/0/0 0/0/4 0.04 6/6/26 7/7/26 PFS: 1.9/1.9/1.8 months OS: 7.1/11.0/8.8 months PFS rate at 16 weeks: 13.3/5.9/19.7%
14 Lung (NSCLC) IPI-504 400 mg/m2 IVD days 1, 4, 8 and 11 of a 21-day cyclei 2 5j 0 5 0.07 18 NA PFS: 2.86 months DR: 120 days
15 GIST BIIB021 12 patients: 600 mg p.o. twice a week of a 28-day cycle 11 patients: 400 mg p.o. three times a week of a 28-day cycle NA 3k/2 0 5 0.12 4/2l 6/4 NA DR:25-138 days

Patients enrolled in two groups whether exposure to gemcitabine or not, which also apply to the following data.

One patient of minimal response in the 340 mg/m2 dose group and two patients of PR in the 175 mg/m2 dose group.

Nine patients from the clear-cell RCC cohort and five patients from the papillary RCC cohort, which also apply to the following data.

Patients with KRAS G12V mutations.

Subtype of ER(+)/HER-2(−), HER-2(+) and TNBC, which also apply to the following data.

Subtype of mutant EGFR, mutant KRAS and no EGFR or KRAS mutations, which also apply to the following data.

Cycle 1 was defined receiving at least two doses of IPI-504.

A reduced dose of 300 mg/m2 due to two mortalities were assessed by the investigator.

Due to hepatotoxicities observed at the 400 mg/m2 dose in a separate trial of IPI-504 in patients with GI stromal tumors, the last enrolled patient started at a dose of 225 mg/m2.

For EGFR status, four patients had EGFR wild-type and one patient had EGFR mutations; for KRAS status, three patients had KRAS wild-type; for ALK status, two patients had ALK rearrangement and one patient had ALK wild-type

evaluated by FDG-PET criteria

evaluated by RECIST and Choi criteria. PFS, progression-free survival; OS, overall survival; TTP, time to progress; NA, not available; DR, response of duration; NSCLC, non-small cell lung cancer; GIST, gastrointestinal stromal tumors; IVD, intravenous dose; RCC, renal cell carcinoma; ER, estrogen receptor; HER, human epidermal growth factor receptor; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; OR, objective response; ORR, objective response rate; 17-AAG, 17-allylamino-17-demthoxygeldanamycin; IPL-504, retaspimycin HCl; ALK, anaplastic lymphoma kinase.

HSP90 inhibitor used in tumors harboring genomic alteration.

Responsea
Trial Drug Cancer status Genotype Prior therapya Total CR PR SD PD Others (c)
1 17-AGG Locally advanced or metastatic breast cancer TNBC (n=6); HER2(+) (n=0) Chemotherapy (all); hormonal (all); bevacizumab (n=1); lapatinib (n=1) 11(7b) 0 0 3 4 PFS: 1 month OS: 10 months
2 17-AGG + Trastuzumab Advanced trastuz-umab-refractory breast cancer HER2(+) (all) Chemotherapy (n=25); trastuzumab (all) 31(27b) 0 6 10 11 PFS: 6 months OS: 17 months DR: 147 days
5 17-AGG Metastatic melanoma Wild-type BRAF (n=6); V600E BRAF (n=9) Chemotherapy (n=5/9) 15 0 0 1 14 NA
6 Ganetespib Stage IIIB/IV NSCLC Mutant EGFR (n=15); mutant KRAS (n=17); no EGFR or KRAS mutations (n=66) Systemic therapy (all); TKI (mutant EGFR, n=14) 98 0/0/0 0/0/4c 6/6/26 7/7/26 PFS: 1.9/1.9/1.8 months PFS rate at 16 weeks: 13.3/5.9/19.7%
7 Ganetespib Metastatic breast cancer ER(+)/HER2(−) (n=6); HER2(+) (n=13); TNBC (n=3) Chemotherapy (all); trastuzumab (HER2(+), n=12) 22 0/0/0 0/2/0 0/6/1 NA PFS: 7 weeks OS: 46 weeks
8 Ganetespib Metastatic colorectal cancer KRAS wild (n=6); KRAS mutant (n=10) Chemotherapy (all); anti-EGFR therapy (KRAS wild-type) 17 0/0 0/0 0/2 NA PFS: 1.6 months 6-month OS: 41% OS: 5.1 months
10 IPI-504 Advanced or metastatic breast cancer HER2(+) (all) Chemotherapy (all); trastuzumab (all) 26 0 0 16 NA NA
11 IPI-504 Stage IIIB/IV NSCLC EGFR (wild/mutant) (n=40/28); KRAS (wild/mutant) (n=26/12); ALK (wild/rearranged) (n=12/3) Systemic therapy (all); TKI (all) 76 0/00/00/0 4/13/01/2 10/64/53/3 NA NA PFS: 2.86/2.76 months 2.86/3.91 months 2.86 months/NA
12 BIIB021 GIST refractory to imatinib and sunit-inib KIT exon 11 mutation (n=7); KIT exon 9 mutation (n=1); no detected PDGFRA or KIT mutation (n=1); unknown mutation status (n=14) Imatinib (all); sunitinib sorafenib (n=14); nilotinib (n=2) 23 0 5 10 NA

The data separated by separator according to genotype sequence.

Median: data are median values.

Patients with ALK rearrangement. PFS, progression-free survival; OS, overall survival; TTP, time to progress; NA, not available; DR, response of duration; NSCLC, non-small cell lung cancer; GIST, gastrointestinal stromal tumors; ER, estrogen receptor; HER, human epidermal growth factor receptor; TKIs, tyrosine kinase inhibitors; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; OR, objective response; ORR, objective response rate; 17-AAG, 17-allylamino-17-demthoxygeldanamycin; IPL-504, retaspimycin HCl; PDGFRA, Platelet-derived growth factor receptor α; ALK, Anaplastic lymphoma kinase.